Navidea Biopharmaceuticals, Inc. (NAVB)

OTCMKTS: NAVB · Delayed Price · USD
0.0000
-0.0300 (-100.00%)
May 23, 2024, 11:53 AM EDT - Market open
Market Cap 100.00
Revenue (ttm) 610
Net Income (ttm) -2.54M
Shares Out 100.08M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 86,563
Open 0.0140
Previous Close 0.0300
Day's Range n/a
52-Week Range n/a
Beta 1.13
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2023

About NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optica... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 1992
Employees 11
Stock Exchange OTCMKTS
Ticker Symbol NAVB
Full Company Profile

Financial Performance

In 2022, NAVB's revenue was $65,652, a decrease of -87.65% compared to the previous year's $531,513. Losses were -$17.22 million, 46.7% more than in 2021.

Financial Statements

News

Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations.

4 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release.

6 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock.

8 months ago - Business Wire

NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to suspend trading in the common stock of Navidea Biop...

8 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel.

10 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities.

10 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination.

10 months ago - Business Wire

NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of ...

10 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer.

10 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

11 months ago - Business Wire

Navidea Biopharmaceuticals rejects ProPhase Labs offer

Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navi...

Other symbols: PRPH
11 months ago - Market Watch

Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

DUBLIN, Ohio--(BUSINESS WIRE)--Following the Company's Fix, Fund, Propel approach, the proposal substantially undervalues Navidea and is not in the best interests of stockholders.

11 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment.

Other symbols: CAH
1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update.

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L.

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down.

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

DUBLIN, Ohio--(BUSINESS WIRE)--New Existing Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market.

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer.

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

1 year ago - Business Wire

Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

1 year ago - Business Wire

Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

1 year ago - Business Wire

Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

1 year ago - Business Wire